Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults
Lianpan Dai, Lidong Gao, Lifeng Tao, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 22, pp. 2097-2111
Open Access | Times Cited: 222

Showing 1-25 of 222 citing articles:

Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Kun Xu, Ping Gao, Sheng Liu, et al.
Cell (2022) Vol. 185, Iss. 13, pp. 2265-2278.e14
Open Access | Times Cited: 113
Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials
Zhirong Yang, Yi-Wen Jiang, Fu-Xiao Li, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 4, pp. e236-e246
Open Access | Times Cited: 89
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama
Vaccines (2023) Vol. 11, Iss. 3, pp. 682-682
Open Access | Times Cited: 59
Accelerating the prediction and discovery of peptide hydrogels with human-in-the-loop
Tengyan Xu, Jiaqi Wang, Shuang Zhao, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 53
Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
Liyan Guo, Sheng Lin, Zimin Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 44
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Fatemeh Bayani, Negin Safaei Hashkavaei, Sareh Arjmand, et al.
Progress in Biophysics and Molecular Biology (2023) Vol. 178, pp. 32-49
Open Access | Times Cited: 40
An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza
Man Xing, Gaowei Hu, Xiang Wang, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 16
Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses
Rory A. Hills, Tiong Kit Tan, Alexander A. Cohen, et al.
Nature Nanotechnology (2024) Vol. 19, Iss. 8, pp. 1216-1223
Open Access | Times Cited: 15
Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
Xiaodi Wu, Ke Xu, Ping Zhan, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 14
A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus
Min Lin, Yifan Yin, Xiaomeng Zhao, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis
Weihao Shao, Xiaorui Chen, Caifang Zheng, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2383-2392
Open Access | Times Cited: 62
Does the World Still Need New Covid-19 Vaccines?
Hanna Nohynek, Annelies Wilder‐Smith
New England Journal of Medicine (2022) Vol. 386, Iss. 22, pp. 2140-2142
Open Access | Times Cited: 45
Immune imprinting and next-generation coronavirus vaccines
Chloe Qingzhou Huang, Sneha Vishwanath, George Carnell, et al.
Nature Microbiology (2023) Vol. 8, Iss. 11, pp. 1971-1985
Closed Access | Times Cited: 38
Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
Dedong Li, Minrun Duan, Xiao Wang, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 12, pp. 1142-1145
Open Access | Times Cited: 36
Affinity Exploration of SARS-CoV-2 RBD Variants to mAb-Functionalized Plasmonic Metasurfaces for Label-Free Immunoassay Boosting
Fajun Li, Junping Hong, Chaoheng Guan, et al.
ACS Nano (2023) Vol. 17, Iss. 4, pp. 3383-3393
Closed Access | Times Cited: 26
Adjuvants for COVID-19 Vaccines
Javier Castrodeza, Ivan Sanz‐Muñoz, José María Eirós Bouza
Vaccines (2023) Vol. 11, Iss. 5, pp. 902-902
Open Access | Times Cited: 25
Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages
Yuliang Wang, Yiyin Long, Feng Wang, et al.
International Journal of Medical Sciences (2023) Vol. 20, Iss. 1, pp. 151-162
Open Access | Times Cited: 23
Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies
Qingwen He, Yaling An, Xuemei Zhou, et al.
Med (2024) Vol. 5, Iss. 5, pp. 401-413.e4
Closed Access | Times Cited: 11
Injectable Hydrogel Mucosal Vaccine Elicits Protective Immunity against Respiratory Viruses
Wenjiao Fu, Mengyu Guo, Xuemei Zhou, et al.
ACS Nano (2024) Vol. 18, Iss. 17, pp. 11200-11216
Closed Access | Times Cited: 10
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 9
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 9
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
Pengfei Jin, Xiling Guo, Wei Chen, et al.
PLoS Medicine (2022) Vol. 19, Iss. 5, pp. e1003953-e1003953
Open Access | Times Cited: 34
Immune Response to SARS-CoV-2 Vaccines
Navya Bellamkonda, Upendra P. Lambe, Sonali Sawant, et al.
Biomedicines (2022) Vol. 10, Iss. 7, pp. 1464-1464
Open Access | Times Cited: 32
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
Shixia Wang, Chang Yi Wang, Hui-Kai Kuo, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2724-2734
Open Access | Times Cited: 31
Efficacy and safety of COVID‐19 vaccines: A network meta‐analysis
Ahmad A. Toubasi, Thuraya N. Al‐Sayegh, Yazan Y. Obaid, et al.
Journal of Evidence-Based Medicine (2022) Vol. 15, Iss. 3, pp. 245-262
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top